292 related articles for article (PubMed ID: 2883885)
1. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
[TBL] [Abstract][Full Text] [Related]
2. Comparison of famotidine with cimetidine and ranitidine.
Berardi RR; Tankanow RM; Nostrant TT
Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
[TBL] [Abstract][Full Text] [Related]
3. Famotidine in the USA: a review of efficacy studies.
Gitnick G
J Int Med Res; 1989; 17 Suppl 1():17A-24A. PubMed ID: 2566539
[TBL] [Abstract][Full Text] [Related]
4. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
Campoli-Richards DM; Clissold SP
Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864
[TBL] [Abstract][Full Text] [Related]
5. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
[TBL] [Abstract][Full Text] [Related]
6. Famotidine: effective treatment of Zollinger-Ellison syndrome.
Howard JM; Vinayek R; Maton PN; Wank SA; Gardner JD; Jensen RT
J Clin Gastroenterol; 1987; 9 Suppl 2():23-5. PubMed ID: 2887615
[TBL] [Abstract][Full Text] [Related]
7. Famotidine in the therapy of gastric hypersecretory states.
Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of H2-receptor antagonists: an overview.
Schunack W
J Int Med Res; 1989; 17 Suppl 1():9A-16A. PubMed ID: 2566544
[TBL] [Abstract][Full Text] [Related]
9. Acid secretion and acid suppression in pathogenesis and healing of peptic ulcer disease.
Thomson AB
Hepatogastroenterology; 1990 Jul; 37 Suppl 1():18-28. PubMed ID: 1976583
[TBL] [Abstract][Full Text] [Related]
10. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
Fiorucci S; Clausi GG; Farinelli M; Santucci L; Farroni F; Pelli MA; Morelli A
Am J Gastroenterol; 1988 Dec; 83(12):1371-5. PubMed ID: 2904218
[TBL] [Abstract][Full Text] [Related]
11. Clinical review of histamine2 receptor antagonists.
Lipsy RJ; Fennerty B; Fagan TC
Arch Intern Med; 1990 Apr; 150(4):745-51. PubMed ID: 1970232
[TBL] [Abstract][Full Text] [Related]
12. [Nizatidine].
Romero M; Franzosi MG
Medicina (Firenze); 1989; 9(1):93-6. PubMed ID: 2567957
[TBL] [Abstract][Full Text] [Related]
13. Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience.
Bianchi Porro G
Digestion; 1985; 32 Suppl 1():62-9. PubMed ID: 2866137
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Maton PN; Gardner JD; Jensen RT
Gastroenterol Clin North Am; 1989 Dec; 18(4):847-63. PubMed ID: 2575602
[TBL] [Abstract][Full Text] [Related]
15. Famotidine in the treatment of duodenal ulcers resistant to other histamine H2-receptor antagonists.
Chen PH; Wang TH; Wang CY; Chen CY; Cheng TC; Tsai YT; Siauw CP; Yang KC; Chen GH; Sung JL
J Int Med Res; 1989; 17 Suppl 1():25A-31A. PubMed ID: 2566541
[TBL] [Abstract][Full Text] [Related]
16. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
Langtry HD; Grant SM; Goa KL
Drugs; 1989 Oct; 38(4):551-90. PubMed ID: 2573505
[TBL] [Abstract][Full Text] [Related]
17. H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection.
Freston JW
Am J Gastroenterol; 1987 Dec; 82(12):1242-9. PubMed ID: 2891294
[TBL] [Abstract][Full Text] [Related]
18. [Famotidine versus placebo in prevention of the recurrence of duodenal ulcer disease. A multicenter study in Germany, Austria and Italy].
Baglioni A; Barbara L; Bianchi-Porro G; Blasi A; Canelli B; Cheli R; Dal Monte R; Dammann HG; Francavilla A; Hentschel E
Z Gastroenterol; 1985 Dec; 23(12):665-9. PubMed ID: 2868581
[TBL] [Abstract][Full Text] [Related]
19. [Strong inhibition of gastric acid secretion: when is it justifiable?].
Dobrilla G; Amplaz S; Benvenuti S; Bertozzo A
G Clin Med; 1990; 71(8-9):521-6. PubMed ID: 1980653
[No Abstract] [Full Text] [Related]
20. [24-hour intragastric acid profile in a ZES patient with H2 blockers].
Dammann HG; Müller P; Simon B; Kommerell B
Z Gastroenterol; 1984 Jun; 22(6):318-20. PubMed ID: 6147052
[No Abstract] [Full Text] [Related]
[Next] [New Search]
